Undervalued Drug Manufacturer Stocks on NYS January 2024

January 13, 2024

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

New York Stock Exchange

The New York Stock Exchange, located in New York City, is the largest securities exchange in the world by market capitalization of its listed companies.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
BMY Bristol-Myers Squibb 50.66 82.33 62.52 16692992 104562 4.60 12.7
TEVA Teva Pharmaceutical Indus 11.49 17.50 52.33 9182352 13041 0.00 0.0
PFE Pfizer 28.99 43.81 51.14 57304190 163678 5.77 15.5
OGN Organon 17.20 25.53 48.42 5208453 4409 6.65 7.4
PRGO Perrigo 33.34 49.23 47.66 1828534 4564 3.31 411.9
ELAN Elanco Animal Health 15.21 20.78 36.60 5610873 7494 0.00 0.0
TAK Takeda Pharmaceutical 14.88 17.85 19.99 1848946 46583 4.21 35.9
GSK GSK 39.99 43.49 8.75 2809568 82219 3.54 10.5
HLN Haleon 8.67 9.37 8.02 3973362 40032 1.20 25.3
ZTS Zoetis 198.77 208.78 5.04 1700067 91712 0.76 40.1
All data provided as at market close January 10, 2024.

Company Details

Bristol-Myers Squibb

BMY:NYS

Close Price

50.66

Our Valuation

82.33

% Difference

62.52

Market Cap ($M)

104562

P/E Ratio

12.7

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Access the stockcalc valuation


Teva Pharmaceutical Indus

TEVA:NYS

Close Price

11.49

Our Valuation

17.50

% Difference

52.33

Market Cap ($M)

13041

P/E Ratio

0.0

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel.

Access the stockcalc valuation


Pfizer

PFE:NYS

Close Price

28.99

Our Valuation

43.81

% Difference

51.14

Market Cap ($M)

163678

P/E Ratio

15.5

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales.

Access the stockcalc valuation


Organon

OGN:NYS

Close Price

17.20

Our Valuation

25.53

% Difference

48.42

Market Cap ($M)

4409

P/E Ratio

7.4

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Perrigo

PRGO:NYS

Close Price

33.34

Our Valuation

49.23

% Difference

47.66

Market Cap ($M)

4564

P/E Ratio

411.9

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS.

Access the stockcalc valuation


Elanco Animal Health

ELAN:NYS

Close Price

15.21

Our Valuation

20.78

% Difference

36.60

Market Cap ($M)

7494

P/E Ratio

0.0

Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Access the stockcalc valuation


Takeda Pharmaceutical

TAK:NYS

Close Price

14.88

Our Valuation

17.85

% Difference

19.99

Market Cap ($M)

46583

P/E Ratio

35.9

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Access the stockcalc valuation


GSK

GSK:NYS

Close Price

39.99

Our Valuation

43.49

% Difference

8.75

Market Cap ($M)

82219

P/E Ratio

10.5

In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Access the stockcalc valuation


Haleon

HLN:NYS

Close Price

8.67

Our Valuation

9.37

% Difference

8.02

Market Cap ($M)

40032

P/E Ratio

25.3

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories.

Access the stockcalc valuation


Zoetis

ZTS:NYS

Close Price

198.77

Our Valuation

208.78

% Difference

5.04

Market Cap ($M)

91712

P/E Ratio

40.1

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Bristol-Myers Squibb and Teva Pharmaceutical Indus are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-january-2024
Bristol-Myers Squibb $BMY and Teva Pharmaceutical Indus $TEVA are the most undervalued Drug Manufacturers stocks on the #NYS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-january-2024
Bristol-Myers Squibb and Teva Pharmaceutical Indus are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-january-2024

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.